High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy by Magnussen, Gry Irene et al.
High Expression of Wee1 Is Associated with Poor
Disease-Free Survival in Malignant Melanoma: Potential
for Targeted Therapy
Gry Irene Magnussen
1, Ruth Holm
1, Elisabeth Emilsen
1, Anne Katrine Ree Rosnes
1, Ana Slipicevic
1,2, Vivi
Ann Flørenes
1*
1Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway, 2The Wistar Institute, Philadelphia, Pennsylvania, United States of America
Abstract
Notoriously resistant malignant melanoma is one of the most increasing forms of cancer worldwide; there is thus a
precarious need for new treatment options. The Wee1 kinase is a major regulator of the G2/M checkpoint, and halts the cell
cycle by adding a negative phosphorylation on CDK1 (Tyr15). Additionally, Wee1 has a function in safeguarding the genome
integrity during DNA synthesis. To assess the role of Wee1 in development and progression of malignant melanoma we
examined its expression in a panel of paraffin-embedded patient derived tissue of benign nevi and primary- and metastatic
melanomas, as well as in agarose-embedded cultured melanocytes. We found that Wee1 expression increased in the
direction of malignancy, and showed a strong, positive correlation with known biomarkers involved in cell cycle regulation:
Cyclin A (p,0.0001), Ki67 (p,0.0001), Cyclin D3 (p=0.001), p21
Cip1/WAF1 (p=0.003), p53 (p=0.025). Furthermore, high Wee1
expression was associated with thicker primary tumors (p=0.001), ulceration (p=0.005) and poor disease-free survival
(p=0.008). Transfections using siWee1 in metastatic melanoma cell lines; WM239
WTp53, WM45.1
MUTp53 and LOX
WTp53, further
support our hypothesis of a tumor promoting role of Wee1 in melanomas. Whereas no effect was observed in LOX cells,
transfection with siWee1 led to accumulation of cells in G1/S and S phase of the cell cycle in WM239 and WM45.1 cells,
respectively. Both latter cell lines displayed DNA damage and induction of apoptosis, in the absence of Wee1, indicating
that the effect of silencing Wee1 may not be solely dependent of the p53 status of the cells. Together these results reveal
the importance of Wee1 as a prognostic biomarker in melanomas, and indicate a potential role for targeted therapy, alone
or in combination with other agents.
Citation: Magnussen GI, Holm R, Emilsen E, Rosnes AKR, Slipicevic A, et al. (2012) High Expression of Wee1 Is Associated with Poor Disease-Free Survival in
Malignant Melanoma: Potential for Targeted Therapy. PLoS ONE 7(6): e38254. doi:10.1371/journal.pone.0038254
Editor: Keiran Smalley, The Moffitt Cancer Center & Research Institute, United States of America
Received January 16, 2012; Accepted May 2, 2012; Published June 12, 2012
Copyright:  2012 Magnussen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was financially supported by The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) and The Norwegian Cancer Cluster. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vivi.ann.florenes@radiumhospitalet.no
Introduction
Malignant melanoma is the second most increasing form of
cancer in Norway, following prostate (men) and lung cancer
(women) [1]. Whereas the prognosis is good when detected early,
there are no curative treatments once the cancer has spread to
distant organs (stage IV). Thus, there is a desperate need for new
and more effective treatment options.
The cell cycle is the orderly series of events leading to cell
division, and is regulated by the assembly and activation of
complexes of CDKs and cyclins, which again triggers the
transition between each of the four phases; Gap 1 (G1), DNA
synthesis (S), Gap 2 (G2) and mitosis (M). During these events,
DNA damages may arise both as a consequence of normal
metabolic activity and due to environmental factors, and division
may be arrested/delayed at three major DNA damage checkpoints
(G1/S, intra- S and G2/M) before cell division. The G1/S
checkpoint is largely controlled by p53, a tumor suppressor protein
which function is impaired/lost in the majority of cancers, thus
compromising this checkpoint. Hence most cancer cells exposed to
DNA-damage rely on the S- and G2/M checkpoints for repair to
occur. Encountering the S-phase checkpoint, genomic insults
cause cells to slow down cell cycle progression rather than being
arrested, rendering the G2/M checkpoint to ultimately halt the cell
cycle progression [2]. Central in regulating the transition between
the G2 and M phases is Wee1-like protein kinase (Wee1), a
tyrosine kinase [3]. Wee1 negatively regulates entry into mitosis by
phosphorylating the Tyr15 residue of Cyclin Dependent Kinase 1
(CDK1, also known as CDC2), thus inactivating the CDK1/cyclin
B complex and arresting the cell cycle.
In addition to being a key regulator of the G2/M checkpoint,
Wee1 also plays an active role in stabilizing the genome in the S-
phase. By suppressing CDK2 activity during DNA synthesis, Wee1
prevents unscheduled initiation of replication that may potentially
lead to DNA lesions [4].
Kinases, such as Wee1, represents potential therapeutic targets,
however, their expression varies in different types of tumors. Over-
expression of Wee1 has previously been reported in osteosarcoma,
glioblastoma and breast cancer [5–7]. Under-expression, on the
other hand, has been described in non-small-cell lung cancer [8].
Cell lines showing an enhanced level of Wee1 have also been
demonstrated to be more sensitive to treatment with siWee1 [6].
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MK1775 have very recently been included in two phase I clinical
trials both as mono-therapy and in combination with either 5-
fluorouracil [9] or topotecan/cisplatin [10].
In the present study, we demonstrate for the first time that
Wee1 is up-regulated in human malignant melanomas as
compared to normal melanocytes and benign nevi, and that high
expression of Wee1 is associated with poor disease-free survival
and markers of increased tumor cell proliferation. Our in vitro
results further revealed a reduced amount of viable cells,
accumulation of cells in G1/S or S-phase and double-strand
DNA breaks following transfection with siWee1 in both p53 wild-
type and mutated melanoma cell lines. Together our results
indicate a role of Wee1 in proliferation and genomic stability in
malignant melanoma, thus potentially making the kinase an
eligible therapeutic target.
Materials and Methods
Speciments
Formalin-fixed, paraffin-embedded tissue sections from 108
primary malignant melanomas (75 superficial spreading (SSM)
and 33 nodular melanomas (NM)), 23 metastases and 10 benign
nevi (7 combined, 2 combined+intradermal and 1 intradermal)
were randomly collected from the archives of The Norwegian
Radium Hospital and regional hospitals. Clinical follow-up was
available for all patients. The Regional Committee for Medical
Research Ethics South of Norway (S-06151) and The Social and
Health Directorate (06/2733) approved the current study proto-
col.
Immunohistochemical analysis
Three-mm sections made from formalin-fixed paraffin embed-
ded tissues were immunostained using the Dako EnVision
TMFlex+
System (K8012, Dako Glostrup, Denmark). Deparaffinization,
rehydration and target retrieval were performed in one operation
in a Dako PT-link and EnVision
TM Flex target retrieval solution
with high pH. To block endogenous peroxidase the sections were
treated with Dako EnVision Peroxidase Block for 5 minutes.
Sections were incubated with monoclonal Wee1 antibody (B-11,
sc-5285, 1:300, 0.67 mg IgG1/mL) from Santa Cruz Biotechnol-
ogy, Inc.(CA, USA) for 30 minutes. Thereafter, the sections were
incubated with Dako EnVision
TM FLEX+ mouse linker for
15 minutes followed by incubation with Dako EnVision
TM
FLEX/HRP for an additional 30 minutes. For visualization of
staining, the sections were treated with 393-diaminobenzidine
tetrahydrochloride (DAB) Chromogen (Dako), counterstained with
haematoxylin, dehydrated and mounted from xylol with Richard-
Allan Scientific Cyto seal XYL (Thermo scientific, MA, USA).
Sections from normal placenta with known expression of Wee1
was used as positive control, whereas negative controls included
substitution of monoclonal antibody with mouse myeloma protein
of the same subclass and concentration as anti-Wee1. Four
semiquantitative classes were used to describe the number of
stained tumor cells: absent, 0; ,10%, 1; 10–50%, 2; .50%, 3.
Staining in cytoplasm and nucleus were evaluated separately.
Wee1 expression in more than 10% of the tumor cells was
considered as high. The expression pattern of Wee1 was compared
to proteins previously examined in our melanoma panel, where
high expression has been set as .5%: Cyclin A [11], Ki67 [11],
Cyclin D3 [12], Cyclin D1 [12], p27 [13] p21
CIP1/WAF1 [14] and
p53 [15].
Statistical analysis
Statistical analysis was performed using of SPSS version 18.0
(Chicago, IL). The relationship between the expression level of
Wee1 and tumor thickness was evaluated non-parametrically using
the Mann-Whitney two sample test. Comparison between Wee1
expression and Ki-67, Cyclin A,- D1,- D3, p21
CIP1/WAF1, p27
kip1,
p53 as well as SSM and NM, was conducted by the use of chi-
square tests. Kaplan-Meier survival estimate was used to evaluate
the impact on survival.
Melanocytes isolation
Normal melanocytes were isolated from human foreskins.
Briefly, foreskins derived from circumcisions of newborns were
washed with Hanks’ balanced salt solution (HBSS) (Invitrogen,
Carlsbad, CA). Excess adipose tissues were removed, and the skin
specimens were cut into approximately 0.560.5 cm
2 pieces and
incubated in 0.48% dispase II (Invitrogen) at 4uC. After 18 hours,
the epidermis was manually removed from the dermis, cut and
digested in 0.05% trypsin for 5 min in 37uC. The suspensions were
diluted in 254CF medium (Invitrogen) and serially filtered through
40 mm cell strainers (Becton Dickinson, Franklin Lakes, NJ). The
cells were plated in the T25 flask and cultured until confluence was
reached. Differential trypsinization was used for first passage in
order to obtain a pure melanocyte culture. Once confluent, 2610
6
melanocytes were harvested using EDTA, embedded in 200 mL
1.5% agarose and fixed in 10% neutral buffered formalin for
1 hour, and processed by routine histological methods.
Cell lines and Growth conditions
The human metastatic melanoma cell lines WM45.1 and
WM239 were kindly provided by Dr. Meenhard Herlyn (the
Wistar institute, Philadelphia, USA) [16,17]. The LOX cell line
was established from a lymph node biopsy of a melanoma
metastasis, at the Norwegian Radium Hospital (Oslo University
Hospital, Norway) [18]. All cell lines were maintained in RPMI-
1640 medium (LONZA, Verviers, Belgium) supplemented with
5% Fetal Calf Serum (Biochrom, KG, Berlin, Germany) and
2 mM L-glutamine (LONZA, Verviers, Belgium). The cells were
grown in monolayer culture at 37uC in humidified conditions
containing 5% CO2 and 95% air.
Small interfering RNA (siRNA) transfection
All cell lines were plated out in either 6-well plates (1.5610
5
cells/well) or in 96-well plates (5610
3 cells/well) 24 hrs in advance
of the transfection. The cells were transfected with 10 nM siRNA
targeting Wee1 (OligioID; ‘VHS50841’) or RNAi negative control
duplexes (Negative Control LOW GC, 12935-200) using Lipo-
fectamine
TM RNAiMAX transfection reagents (all reagents from
Invitrogen corporation, CA, USA).
MTS assay
Five thousand cells per well were seeded in 96-well plates and
left to attach overnight, before siRNA transfection for the
indicated time.
Cell viability was determined using the 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
(MTS) assay (Promega, WI, USA), in which the capacity of the
cells to convert MTS salt into a brown formazan product was
measured. Absorbance was measured at 490 nm using ASYS
UVM340 96-well plate reader.
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Cells treated with SiCtr or SiWee1 were harvested using
trypsin/EDTA (LONZA), along with medium containing floating
cells. After centrifugation, the cell pellet was resuspended in PBS
containing trypan blue (Merck, Stockholm, Sweden). Viable (dye
excluding) and trypan blue stained dead cells were counted.
Cell Death Detection ELISA
plus
Determination of cytoplasmic histone-associated-DNA-frag-
ments was assessed using a commercially available kit (Roche
Diagnostic GmbH, Mannheim, Germany), following the manu-
facturers instructions. The presence of histones in cytoplasm is
indicative of apoptosis. The ELISA signal was quantified by
measuring the absorbance at 405 nm (reference 495 nm), using
ASYS UVM340 96-well plate reader (Fisher Scientific, Oslo,
Norway).
Flow cytometric cell cycle analysis
Cells were harvested by trypzination and washed 16 in PBS.
Cell pellets containing approximately 10
6 cells were re-suspended
in 1 mL 70% ice-cold methanol and left to fixate for a minimum
of 24 hrs. Fixated cells were washed 16in PBS, and stained with a
solution containing 2 mg/mL Hoechst 33258 in PBS. Flow
cytometric analysis was performed using LSR II UV laser (BD
biosciences, San Jose, CA).
Western blot analysis
Cells were harvested using a rubber policeman, washed once in
16PBS, and then lysed in ice-cold NP-40 Lysis buffer (1% NP-40,
10% glycerol, 20 mM Tris-HCl (pH 7.5), 137 mM NaCl,
100 mM NaF), Aprotenin (0.02 mg/mL), Phosphatase inhibitor
cocktail 1 (10 mL/mL), Phosphatase inhibitor cocktail 2 (10 mL/
mL), PhenylMethaneSulfonyl Fluoride (PMSF) (1 mM), Leupeptin
(0.02 mg/mL), Pepstatin (0.02 mg/mL) and Sodium vanadate
(1 mM) (Sigma-Aldrich, St. Louis, MO)). Bradford (Bio-Rad
Laboratories AB, Sundbyberg, Sweden) analysis was performed
for protein quantification, and 25 mg protein/lane was resolved in
SDS polyacrylamide gel electrophoresis (PAGE) and transferred to
a PDVF immobilon membrane (Millipore, Bedford, MA). To
ensure even loading, filters were stained with naphtholblue black
(Sigma-Aldrich) and later re-stained with a-tubulin. The mem-
branes were blocked in 5% non-fat milk in TBST (150 mM NaCl,
25 mM Tris-Cl, (pH 7.5), 0.01% Tween 20), and probed with
primary antibodies at 4uC overnight, with gentle agitation.
Primary antibodies Caspase 3 (#9662/#9664 (even mix)),
Caspase 8 (#9746), Caspase 9 (#9502), Cyclin B1 (#4138S),
Cyclin D3 (#2936), p21
CIP1/WAF1 (#2946), p-p38 Thr180/
Tyr182 (#4631) and PARP (#9532), were purchased from Cell
Signaling (Beverly, MA). a-tubulin (DMIB) was acquired from
Calbiochem (Nottingham, UK), whereas Cyclin A (sc-751), p53
(sc-126) and Wee1 (sc-5285) were obtained from Santa Cruz
(Santa Cruz, CA). c-H2AX (#05-636) and pCDK1
Tyr15
(ab47594) antibodies were acquired from Millipore and Abcam
(Cambridge, England), respectively. Membranes were thereafter
washed 3610 minutes in TBST. Membranes were hybridized
with an appropriate secondary antibody (HPR-conjugated anti-
rabbit or anti-mouse IgG antibodies (Promega)) for 1 hr at room
temperature, with gentle agitation, and then washed in TBST for
3610 minutes. Protein bands were detected after first incubating
the membranes with ECL-plus (GE Healthcare, Chalfont St Gils,
UK) for 5 minutes, and then exposing them to X-ray films.
Results
Increased expression of Wee1 in melanoma
High protein expression of Wee1 has previously been reported
in human cancers [5–7]. Since the status of Wee1 expression in
melanomas has not been extensively studied, paraffin-embedded
tissue from a panel of benign nevi and primary- and metastatic
melanomas, in addition to a sample of cultured melanoncytes,
were analyzed for Wee1 protein expression by immunohistochem-
isty. As illustrated in Figure 1A, protein expression of Wee1 was
hardly detectable in the nucleus of the cultured melanocytes,
however brown granules were seen in the cytoplasm, most likely
due to melanin. Furthermore, as demonstrated in Table 1 and
illustrated in Figure 1A, a heterogeneous Wee1 staining pattern
was observed in the vast majority of the tumor samples. However,
the percentage of positive cells varied in tissues of different stages.
Based on distribution, positive immunoreactivity in $10% of the
tumor cells was used as cut-off to discriminate between high and
low Wee1 expression. Whereas only 20% of the nevi displayed
Wee1 expression in $10% of the tumor cells, this was the case for
42% of the primary- and 70% of the metastatic tumors.
Furthermore, while none of the examined nevi contained .50%
Wee1 immunoreactive cells, such expression was found in 4% of
the primary melanomas and 22% of the metastatic tissues.
Nodular lesions expressed higher levels of Wee1 than the
superficial spreading tumors. Wee1 expression was in all cases,
except two, exclusively localized to the cell nucleus.
High expression of Wee1 is associated with poor
prognosis and increased proliferation
Since expression of Wee1 increased in direction from nevi to
primary- and metastatic melanomas, we next examined the
relationship between Wee1 expression, clinical parameters and
disease outcome. As shown in Table 2, and Figure 1B, high Wee1
expression (in $10% of the tumor cells) was significantly
associated with thicker primary tumors (p=0.001), T-staging
(p=0.004), as well as with ulceration (p=0.005) and poor disease-
free survival (p=0.008). No association with over-all survival was
found (data not shown).
Since our panel of melanomas has been previously analyzed for
other regulators of the cell cycle, we examined the relationship
between Wee1 and expression of these parameters (Ki-67, Cyclin
A,- D1,- D3, p21
CIP1/WAF1, p27
kip1 and p53) [11–15]. As shown in
Table 2, significant co-variations between Wee1 expression and
cyclin A (p,0.0001), Ki67 (p,0.0001), Cyclin D3 (p=0.001), p53
(p=0.025) and p21
CIP1/WAF1 (p=0.003) were detected. No
associations between Wee1 expression and Cyclin D1 and
p27
kip1 were observed (data not shown). Together these results
suggest that high Wee1 protein expression is associated with
increased proliferation in human melanomas.
In vitro results support a role of Wee1 in proliferation and
genome stabilization
To further study the role of Wee1 in melanomas we knocked-
down its expression using siRNA in the three metastatic cell lines,
WM239 (p53-wild-type), WM45.1(p53-mutated) and LOX (p53-
wild-type). Wee1 was effectively silenced in all three cell lines, as
confirmed by western blotting; however, phosphorylation on
Tyr15 of CDK1, a downstream target of Wee1, was only down-
regulated in WM239 and WM45.1 cells (Figure 2A). Decreased
cell viability as estimated by MTS (Figure 2B) and a relative
reduction of living cells (Figure 2C), were observed after 24, 48
and 72 hours of siWee1 transfection in WM239 and WM45.1, but
not in LOX cells.
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cell death in WM 239 and WM 45.1 as determined by the cell
death detection ELISA
plus kit (Figure 3A). Likewise, cleavage of
Poly(ADP-ribose) polymerase (PARP) and pro-caspase-3, markers
of apoptosis [19], were detected in the absence of Wee1
(Figure 3B).
Serine 139 phosphorylation of H2AX (c-H2AX) is a sensitive
marker for DNA double-strand breaks, and may be constitutively
expressed in untreated cells due to oxidative DNA damage during
metabolic activity [20,21]. Expression of c-H2AX was observed in
all cell lines, however in the absence of Wee1, an increase of c-
H2AX was observed in WM239 and WM45.1 cells, indicating
increased DNA damage (Figure 3B).
The p53 tumor suppressor protein accumulate in the presence
of DNA damages, thus leading to DNA repair, cell cycle arrest or
apoptosis [22]. An increase in p53 protein expression was observed
in WM239 (p53
WT) cells following treatment with siWee1, but not
in WM45.1 (p53
MUT) or LOX cells (p53
WT). Notably, these results
indicate that inhibition of Wee1 may sensitize melanoma cell lines
to DNA damage regardless of their p53 status.
Since Wee1 is a key regulator of the G2/M phase transition, we
studied the effect of Wee1 knockdown on cell cycle progression. As
demonstrated in Figure 4A, flow cytometry analysis revealed
accumulation of WM239 and WM45.1 cells in the G1/S- and S-
phase, respectively. The cell cycle distribution was, however, not
affected in siWee1 treated LOX cells. Furthermore, immunoblot-
ting revealed that cyclin D1, -A, and –B1 protein levels were
weakly to moderately down-regulated in WM239 and WM45.1,
but not in LOX cells. Moreover, a marginal decrease in cyclin D3
expression was observed in WM239 cells. Despite increased p53
expression, p21
CIP1/WAF1 protein expression was weakly increased
Figure 1. High Wee1 expression increases with tumor progression and is associated with a shorter relapse-free period. A. Wee1
expression in cultured melanocytes, benign nevi, primary- and metastatic melanoma, analyzed by immunohistochemistry. B. Melanoma patients were
grouped according to Wee1 expression in their tumors (high (n=44) or low (n=63)). Relapse-free survival in months was estimated for both groups
and presented as a Kaplan Meyer curve.
doi:10.1371/journal.pone.0038254.g001
Table 1. Number (percentage) of melanocytic lesions
expressing different levels of Wee1.
Expression
level Low High
No. Analyzed 0% ,10% 10–50% .50%
Nevi 10 0 (0%) 8 (80%) 2 (20%) 0 (0%)
Primary
melanoma
108 3 (3%) 60 (56%) 41 (38%) 4 (4%)
Superficial
spreading
75 1 (0%) 49 (65%) 24 (32%) 1 (0%)
Nodular 33 2 (6%) 11 (33%) 17 (52%) 3 (9%)
Metastatic
melanoma
23 1 (4%) 6 (26%) 11 (48%) 5 (22%)
Wee1 expressions in benign nevi, primary- and metastatic melanoma were
estimated by immunohistochemistry, and categorized in four semi-quantitative
classes according to percentage of immunoreactive tumor cells. The groups
were further divided into low (,10%) and high ($10%) expression.
doi:10.1371/journal.pone.0038254.t001
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cells (Figure 4B). As previously reported, p21
CIP1/WAF1 was not
constitutively expressed in WM45.1 cells, and Wee1 silencing did
not affect its expression [23]. The p38 MAP kinase signaling
pathway has previously been shown to be involved in p53-
independent cell cycle arrest as a response to DNA damage [24],
hence we next examined its activation in the absence of Wee1. In
support of this hypothesis, increased phosphorylation of p38,
indicative of an active signaling pathway, was observed in WM239
and WM45.1, but not in LOX cells, following transfection with
siWee1.
Discussion
In the present study, immunohistochemisty was applied to
examine the level of Wee1 in a panel of benign nevi and primary –
and metastatic melanomas, as well as in one sample of isolated
normal melanocytes, in order to evaluate the impact of altered
expression on disease progression and clinical outcome. We
demonstrate that Wee1 up-regulation follows tumor progression
and is associated with thicker tumors, ulceration and decreased
relapse-free survival. Similar results have previously been reported
in other forms of human cancers, such as glioblastoma and breast
cancer [5,6]. In non-small-cell lung cancer, on the other hand,
reduced Wee1 expression was associated with a higher recurrence
rate [8]. Furthermore, Wee1 showed a strong, positive correlation
with markers of proliferation: Cyclin A, Ki67 and Cyclin D3 [25].
In support, we have previously reported that increased expression
of Ki67, Cyclin A and -D3 is associated with tumor thickness,
progression and poor clinical outcome in melanomas [11,12]. In
line with these findings, our in vitro results demonstrated that in the
absence of Wee1, both Cyclin D1, -D3 (only in WM239) and -A
protein expression were weakly decreased in two out of three
melanoma cell lines. Based on these findings, we hypothesize that
Wee1 contributes to increased proliferation in melanomas.
The augmented expression of Wee1 may seem as a controversy
in malignant tumors, based on its well-known inhibitory role in cell
cycle progression. However, Wee1 also has a role in genomic
stabilization during replication by preventing DNA damage to
occur [26,27]. Furthermore, if other mutations have led to
increased CDK- activity, elevated levels of Wee1 may be beneficial
to avoid premature mitotic entry resulting in cell death [4]. Our in
vitro results using siRNA mediated downregulation of Wee1, led to
increased cell death, thus further emphasizing the association with
malignancy observed in vivo. It is therefore likely that the high
Table 2. Wee1 expression correlates with clinical parameters-
and markers of tumor progression.
Clinical
parameter
No.
Analyzed ExpressionLow High p-value {
Mean tumor
depth
105 1.99 mm 3.90 mm 0.001
T-stage
T1 (0–1 mm) 27 22 (81%) 5 (19%) 0.004
T2 (1.01–2.0 mm) 34 21 (62%) 13 (38%)
T3 (2.01–4 mm) 18 7 (39%) 11 (61%)
T4 (.4 mm) 26 10 (38%) 16 (62%)
Ulceration 100 No 46 (46%) 22 (22%) 0.005
Yes 12 (12%) 20 (20%)
Marker*
Cyclin A 99 Low 39 (39%) 12 (12%) ,0.0001
High 19 (19%) 29 (29%)
Ki67 99 Low 46 (46%) 17 (17%) ,0.0001
High 12 (12%) 24 (24%)
Cyclin D3 99 Low 48 (48%) 21 (21%) 0.001
High 10 (10%) 20 (20%)
p21
Cip1/WAF1 71 Low 30 (42%) 9 (13%) 0.003
High 13 (18%) 19 (27%)
p53 67 Low 38 (57%) 20 (30%) 0.025
High 2 (3%) 7 (16%)
*Low expression of Cyclin A [11], Ki67 [11], Cyclin D3 [12], p21 [13] and p53 [14];
defined as immunoreactivity in ,5% of the tumor cells. Wee1 expression in
,10% of tumor cells is defined as low.
{Statistical significances determined by Chi-square tests.
doi:10.1371/journal.pone.0038254.t002
Figure 2. Transfection with siWee1 effectively shuts down
Wee1 expression and reduces cell viability. A. Cells were
transfected with siWee1 for 48 hours. Expressions of Wee1 and
pCDK1
Tyr15 were examined by western blot analysis. a-tubulin was
used as loading control. The figure is representative of at least three
independent biological experiments.B and C. Cells were transfected
with siWee1 (dots: 24 h, stripes: 48 h and no-pattern: 72 h). The relative
amount of viable cells was estimated by MTS (B), and the relative
quantity of living cells was estimated by counting trypan-excluding cells
(C).
doi:10.1371/journal.pone.0038254.g002
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damage and cell death. In line with this hypothesis, our in vitro
results showed that double-strand DNA damage, as demonstrated
by increased cH2AX expression, occurred in the absence of Wee1
in both WM239 and WM45.1 cells, and was accompanied by
accumulation of cells in the G1/S- and S phases, in the two cell
lines, respectively. In accordance with our results, Dominiguez-
Kelly et al. [27] recently reported augmented amounts of cH2AX
in cells stalled in the S-phase, following treatment with siWee1.
Given its role in maintaining genomic stability in S-phase, we
speculate whether cells lacking Wee1 may fail to regulate CDK
activity during replication, thus leading to DNA damage and S-
phase arrest [26]. Another possible explanation may be that cells
in lack of a functional G2/M checkpoint rush into mitosis without
securing a proper DNA synthesis, potentially leading to so-called
mitotic catastrophe and cell death [7,28].
In accordance with a study by Hashimoto et al. [29], using
Wee1 inhibitor PD0166285 in murine melanoma, silencing of
Wee1 also led to decreased proliferation in WM239 and WM45.1
cells in the present study. Strikingly, the growth inhibitory effect in
murine melanomas was even stronger than what was observed in
our study following siWee1 transfection. However, whereas
siWee1 is believed to be highly specific, PD0166585 is a
nonselective Wee1 inhibitor which even at low concentrations
can target a range of other kinases involved in regulating CDK
activity, such as Membrane-associated tyrosine/threonine protein
kinase 1 (MYT1) and Serine/threonine-protein kinase 1 (CHK1)
[28,30]. The increased effect may also simply be due to the
differences in tumor cell lines. Notably, silencing of Wee1 had no
effect on LOX cells in terms of proliferation, cell death or cell cycle
distribution. However, phosphorylation of its downstream target
CDK1
Tyr15 was not abolished in this cell line, thereby providing a
possible rationale for lack of response to treatment with siWee1.
Hence, we speculate if other mechanisms are more central in
CDK1 regulation in this cell line, for instance MYT1, known from
other cell systems to have much of the same functions as Wee1
[31].
In the present study we found that Wee1 had a strong positive
correlation with p53 expression and p21
CIP1/WAF1 in primary
melanomas. High p53 expression has previously been shown to
correlate with poor clinical outcome and increased proliferation in
metastatic melanoma [32,33], however the opposite has also been
found [34]. Likewise, we have previously reported that p53 protein
expression is increased in metastatic melanoma compared to
benign nevi, however, although not significant, high expression
was also associated with a more favorable disease progression [15].
Despite being mutated in the majority of human cancers,
mutational inactivation of p53 is rare in melanomas; yet the
protein may not function as normal. In this regard, it was shown
that despite being expressed as wild-type in melanoma, p53 could
activate some genes in response to stress, but lacked the ability to
inhibit growth or induce apoptosis [33,35]. Interestingly, our in
vitro results demonstrated that the effects of silencing Wee1 were
not exclusive to p53 mutated cell lines. In contrast to our findings,
effects of inhibiting Wee1 in other cancer forms have in previous
studies been described as limited to cells with mutated p53, in
particular when combined with DNA damaging agents [36–38].
Additionally, p21
CIP1/WAF1, a down-stream target of p53, was
significantly correlated with Wee1 in primary melanomas.
p21
CIP1/WAF1 is a well-known inhibitor of CDKs, and is known
to promote cell-cycle arrest in response to many stimuli, however
the protein may also exhibit oncogenic activities [39]. In line with
this, we have previously demonstrated that p21
CIP1/WAF1 expres-
sion is up-regulated in primary melanomas compared to benign
nevi, and is associated with thicker tumors [14]. When silencing
Wee1 in vitro, p21
CIP1/WAF1 expression increased marginally, in
WM239 cells only, suggesting that the association between Wee1
and p21
CIP1/WAF1 observed in vivo could be due to indirect
mechanisms. However, the accumulation of cells in G1/S phase,
accompanied by increased p21
CIP1/WAF1 protein expression, in
siWee1 treated WM239
p53wt cells, suggests that the augmented
p53 protein level probably is able to trigger the G1/S checkpoint
in response to DNA damage in this cell line. Hence we speculate if
the increased cell death seen in WM239 cells in the absence of
Wee1, is related to the cells inability to control CDK activity
during DNA replication, rather than the ability to stop the cell
cycle progression in G2/M. Notably, Reinhardt et al. has
previously reported that activation of the p38/MAPK signaling
pathway may cause cell cycle arrest after DNA damage in the
absence of p53 [24]. In both WM239 and WM45.1 cells activation
of the p38/MAPK signaling pathway increased in the absence of
Wee1 suggesting that the p38/MAPK signaling pathway may
contribute to the arrest following DNA damages induced by
siWee1.
Figure 3. Transfection with siWee1 promotes DNA damages
and apoptosis. A. Presence of cytoplasmic oligonucleosomes was
measured by ELISA following 48 h siWee1 transfection. Induction of
apoptosis shown as enrichment factor calculated as absorbance at
405 nm of siWee1 treated cells relative to siCtr treated cells. B. Protein
expressions were measured by Western blot following 48 h transfection
with either siCtr or siWee1. Cleavage of PARP and Caspase 3 are shown
with arrows. a-tubulin was used as loading control. The figure is
representative of at least three independent biological experiments.
doi:10.1371/journal.pone.0038254.g003
High Wee1 Correlates with Poor Outcome in Melanoma
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38254In conclusion, our results indicate that despite being an inhibitor
of cell cycle progression, high expression of Wee1 is associated
with malignancy and poor prognosis in patients with melanoma.
Our in vitro results further support these findings; silencing of Wee1
resulted in DNA damage and increased cell death in two out of
three cell lines regardless of p53 status. Thus, high expression of
Wee1 appears to protect the cancer cell from DNA damage and
ultimately cell death. These findings potentially make Wee1 an
eligible target in melanoma, both as mono-therapy and in
combination with DNA damaging agents.
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